Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Metastatic Cutaneous Squamous Cell Carcinoma
NCT02964559Phase 2Completed
- Sponsor
- Emory University
- Start
- Jan 2017
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Emory University. Primary endpoint: Response Rate of Pembrolizumab up to 1 year. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT02964559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964559.